sonidegib

specific Smoothened/Smo antagonist

Also Known As:

(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-; LDE225; N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide; NVP-LDE225; Odomzo

Networked: 190 relevant articles (21 outcomes, 47 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dummer, Reinhard: 12 articles (05/2022 - 04/2014)
2.	Fabbrocini, Gabriella: 10 articles (01/2022 - 06/2020)
3.	Scalvenzi, Massimiliano: 10 articles (01/2022 - 06/2020)
4.	Villani, Alessia: 10 articles (01/2022 - 06/2020)
5.	Costa, Claudia: 8 articles (01/2022 - 06/2020)
6.	Squittieri, Nicholas: 7 articles (12/2021 - 01/2020)
7.	Gutzmer, Ralf: 6 articles (11/2021 - 06/2015)
8.	Sellami, Dalila: 6 articles (01/2017 - 06/2015)
9.	Conforti, Claudio: 5 articles (01/2022 - 11/2020)
10.	Zalaudek, Iris: 5 articles (01/2022 - 11/2020)

Related Diseases

1.	Basal Cell Carcinoma (Rodent Ulcer) 01/01/2022 - "Overall, real-world evidence corroborated sonidegib efficacy and tolerability as a first-line treatment for locally advanced basal cell carcinoma." 06/01/2015 - "The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat. " 06/01/2023 - "Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study." 09/01/2023 - "The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area." 01/01/2022 - "The primary objective was to evaluate the efficacy of sonidegib for treatment of locally advanced basal cell carcinoma in a real-world setting. "
2.	Neoplasms (Cancer) 10/01/2016 - "The purpose of this study was to determine the maximum tolerated dose based on dose-limiting toxicity (DLT) and the recommended dose (RD) of sonidegib in Asian patients with advanced solid tumors. " 10/01/2016 - "Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors." 01/01/2022 - "Of the remaining two patients, treatment with sonidegib arrested tumor progression and decreased tumor size to a point where surgical removal was straightforward. " 09/28/2021 - "Quantitative MRI suggested that LDE225 causes increased tumor diffusion and works particularly well in patients with poor baseline tumor perfusion." 09/28/2021 - "LDE225 is a pharmacological Hedgehog signaling pathway inhibitor and is thought to specifically target tumor stroma. "
3.	Skin Neoplasms (Skin Cancer) 09/01/2023 - "The aim of our study was to evaluate the outcome of sonidegib treatment in patients affected by periocular locally advanced (la) BCC at our skin cancer center. " 09/26/2021 - "Sonidegib (SNG) is a hedgehog inhibitor that has been used for skin cancer treatment. " 09/26/2021 - "Improving the Antitumor Activity and Bioavailability of Sonidegib for the Treatment of Skin Cancer." 07/01/2022 - "This study examined patterns of discontinuation and reinitiation of Hedgehog pathway inhibitors (HHIs) such as vismodegib or sonidegib for patients with basal cell carcinoma, the most common form of skin cancer. " 02/01/2016 - "Fewer drugs like vismodegib, itraconazole and sonidegib have shown promising results inhibiting the awry function of Hh pathway resulting in treatment of different forms of skin cancers. "
4.	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/01/2022 - "Treatment with sonidegib 200 mg/day led to remission in both patients with locally advanced BCC within 7 months and to a reduction in the size and number of lesions after 4 months in the patient with Gorlin syndrome. " 01/01/2020 - "Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial." 08/01/2011 - "In a double-blind, randomized, vehicle-controlled, intraindividual study, a total of 8 NBCCS patients presenting 27 BCCs were treated twice daily with 0.75% LDE225 cream or vehicle for 4 weeks. " 01/01/2022 - "This report describes clinical experience with sonidegib in two patients with locally advanced BCC (one with a tumour adjacent to the right eye and the other with a tumour associated with the left ear) and in one patient with Gorlin syndrome. " 08/01/2011 - "Treatment with 0.75% LDE225 cream in NBCCS patients was very well tolerated and caused BCC regression, thus potentially offering an attractive therapeutic alternative to currently available therapies for this indication.JID JOURNAL CLUB ARTICLE: For questions, answers, and open discussion about this article, please go to http://www.nature.com/jid/journalclub."
5.	Primary Myelofibrosis (Myelosclerosis) 01/01/2020 - "Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study." 01/01/2020 - "The sonidegib and ruxolitinib combination was assessed in an open-label study in JAK inhibitor-naive patients with myelofibrosis (MF). "

Related Drugs and Biologics

1.	sonidegib
2.	HhAntag691
3.	Itraconazole (Sporanox)
4.	Vitamins
5.	ruxolitinib
6.	CUR 61414
7.	177Lu-octreotate
8.	Ligands
9.	Paclitaxel (Taxol)
10.	Fluorouracil (Carac)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Drug Tapering
4.	Prostatectomy (Retropubic Prostatectomy)
5.	Drug Therapy (Chemotherapy)